SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is experiencing a strong rally ahead of its quarterly delivery report, driven by optimistic market expectations that it will significantly outperform analyst estimates. Community sentiment is deeply divided, with bulls pointing to delivery momentum and potential AI catalysts, while bears remain focused on valuation concerns and skepticism surrounding the sustainability of the stock's recent gains.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is seeing active community debate as investors react to strong delivery guidance and reports of successful production ramps for the R2 model. Traders are closely watching key technical resistance levels while debating whether the current momentum represents a long-term fundamental breakout or a short-term volatility play.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is trending as investors debate its long-term growth potential and platform expansion compared to larger brokerage peers, while a vocal community segment focuses on technical support levels and recent institutional accumulation. Sentiment remains deeply divided, with some traders optimistic about a potential breakout driven by platform scaling, while others express frustration over persistent price stagnation and perceived market manipulation.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is trending as the community highlights a major nuclear energy win with Sweden selecting the company's Small Modular Reactors, fueling long-term optimism alongside expectations for upcoming defense contract announcements. Investors are actively discussing the stock's resilient upward momentum and potential for significant growth as a key player in the evolving global aerospace and nuclear infrastructure sectors.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is trending due to heightened community debate over its significant short interest and valuation disconnect compared to industry peers, despite strong international and domestic sales growth for its core portfolio and Alani Nu. Investors are actively discussing the potential for a technical reversal or short squeeze, while keeping a close watch on shifting consumer brand loyalty and the broader rotation of capital into undervalued growth stocks.

McDonald's Corp. engages in the operation and franchising of restaurants. The firm operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. Its products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, and McCafe beverages. The company was founded by Raymond Albert Kroc on April 15, 1955 and is headquartered in Chicago, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is currently a major topic of debate among traders, with many speculating on whether the stock is a defensive value opportunity near historical support or a 'dying' brand facing structural declines. Sentiment remains sharply divided, as investors weigh the potential for technical recovery against concerns over consumer spending, rising commodity costs, and the impact of weight-loss drugs on the fast-food sector.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as retail investors ramp up speculation around upcoming global expansion announcements and potential catalysts in the Middle East, while simultaneously monitoring a high concentration of short interest that community members believe is nearing a squeeze point. Discussions are heavily focused on the clinical potential of NK cell therapies and the anticipation of stronger commercial traction following recent executive travel and manufacturing updates.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as analysts highlight the platform's multi-layered expansion strategy, including global market growth, the launch of Trump-backed investment accounts, and new on-chain financial products. While community sentiment is heavily polarized between bullish supporters betting on long-term platform scale and skeptics wary of high valuations and intense market volatility, the stock remains a central focus for retail traders monitoring institutional upgrades and upcoming corporate events.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster is trending as investors capitalize on the company's expanding role in the physical AI and robotics sectors, bolstered by a significant public stock offering to fund growth and recent strategic successes like its BABA Act certification. The community is actively debating the balance between short-term dilution from the offering and the long-term potential for Ouster to become a foundational sensing layer in automated heavy machinery and smart infrastructure.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY is trending as investors react to a cooling labor market, with the June payroll growth falling short of consensus estimates and fueling speculation that the Federal Reserve may soon pivot toward rate cuts. The community remains deeply divided, with some traders optimistic that weaker economic data serves as a 'Goldilocks' catalyst for further gains, while others express frustration over market volatility, perceived data manipulation, and the potential for a broader bubble in AI-linked sectors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The attachment is a history of all 62 new commercial-stage oncology focused bios since 1/1/2013, and what would have happened to you if you invested $1,000 in all 62 at the time of approval. 
 
Had you invested $1,000 in all 62 at the bio&#39;s closing share price the day after approval was announced, your $62,000 investment would be worth $60,008 today (excluding the time value of money). 
 
As we&#39;ve posted time &amp; again, 18 of the 62 were sold @ gains &amp; 9 of the 62 were sold at a loss (using the bio&#39;s closing share price 1 day post approval). Our summary makes 1 adjustment to reflect those commercial-stage bios sold within 2 years after FDA approval &amp; those that waited for more than 2 years. The data speaks for itself. 
 
The historical evidence is overwhelming, as is common sense, shareholder value of bios in this peer group is maximized via M&amp;A exit within 2 years of FDA approval.  
 
$GERN  
$LEGN  
$KPTI  
$ADCT  
$KURA

Spartrap

splatch

Fort Knox Investments

0wl2000

Georgeson

Daniel Zedek

jay dunn

Brian Devela

StockTwits Web

Geron Corp.

Legend Biotech

Karyopharm Therapeutics Inc

Adc Therapeutics SA

Kura Oncology Inc

The attachment is a history of all 62 new commercial-stage oncology focused bios since 1/1/2013, and what would have happened to you if you invested $1,000 in all 62 at the time of approval. 
 
Had you invested $1,000 in all 62 at the bio's closing share price the day after approval was announced, your $62,000 investment would be worth $60,008 today (excluding the time value of money). 
 
As we've posted time & again, 18 of the 62 were sold @ gains & 9 of the 62 were sold at a loss (using the bio's closing share price 1 day post approval). Our summary makes 1 adjustment to reflect those commercial-stage bios sold within 2 years after FDA approval & those that waited for more than 2 years. The data speaks for itself. 
 
The historical evidence is overwhelming, as is common sense, shareholder value of bios in this peer group is maximized via M&A exit within 2 years of FDA approval.  
 


Night Owl Biotech Research

@Night_Owl_Biotech I don&#39;t see Seagen on your list, are you sure this is complete?

 I don't see Seagen on your list, are you sure this is complete?

Todd Luttenegger

@badprecog  
 
Great catch but remember we started tracking these in 2013. SGEN&#39;s first approval was well before 1/1/13. There are a handful of others like EXEL, CELC, INCY etc. whose first approval was post 1/1/2000 but pre-1/1/2013. 
 
Good, bad, right or wrong we started tracking these data points 1/1/13 (when we officially started our club). 
 
Thank you for the post.

  
 
Great catch but remember we started tracking these in 2013. SGEN's first approval was well before 1/1/13. There are a handful of others like EXEL, CELC, INCY etc. whose first approval was post 1/1/2000 but pre-1/1/2013. 
 
Good, bad, right or wrong we started tracking these data points 1/1/13 (when we officially started our club). 
 
Thank you for the post.

@Night_Owl_Biotech how many were actually profitable?

StockTwits for iOS

Mitchell Johnson

@Night_Owl_Biotech great lesson on BO not guarantee, creating a profitable drug is hard

 great lesson on BO not guarantee, creating a profitable drug is hard

Mike kiM

@Night_Owl_Biotech Thank you sir. You are one of a few here who provides excellent info.

 Thank you sir. You are one of a few here who provides excellent info.

@Night_Owl_Biotech fabulous work. Have you included Relypsa?

 fabulous work. Have you included Relypsa?

@chiefresident  
 
Thank you for the kind words. We track Relypsa with the non-oncology focused peer group. We posted a like schedule for commercial-stage non-oncology focused bios within the last month or so. We will re-publish soon. 
 
Thank you again.

  
 
Thank you for the kind words. We track Relypsa with the non-oncology focused peer group. We posted a like schedule for commercial-stage non-oncology focused bios within the last month or so. We will re-publish soon. 
 
Thank you again.

@Georgeson  
 
Thank you so much for the kind words. We work hard so it is genuinely appreciated.

  
 
Thank you so much for the kind words. We work hard so it is genuinely appreciated.

@kiwiSurfer @KY3000  
 
I cannot think of one, but perhaps BPMC. Patent life always limit the time these bios can generate value. It&#39;s my experience these commercial-stage bios are acquired for scale to the acquirer. 
 
Everyone wins in M&amp;A including &amp; especially the cancer patient community via scale that comes from consolidation to help control the ever rising costs to the healthcare system.

  
 
I cannot think of one, but perhaps BPMC. Patent life always limit the time these bios can generate value. It's my experience these commercial-stage bios are acquired for scale to the acquirer. 
 
Everyone wins in M&A including & especially the cancer patient community via scale that comes from consolidation to help control the ever rising costs to the healthcare system.